(Photo Courtesy: www.thenextweb.com)
Key Highlights (Q2 FY15)
o Consolidated revenues at ₹35.9 billion, year-on-year growth of 7 percent.
• Revenues from the Global Generics (GG) segment at ₹28.9 billion, YoY growth of 9 percent
• Revenues from the Pharmaceutical Services and Active Ingredients (PSAI) segment at ₹6.4 billion.
o Gross Profit Margin at 58.5 percent versus 58.0 percent as in Q2 FY 14.
o Research and Development (R&D) expenses at ₹4.1 billion, 11.5 percent to revenues versus 9.0% to revenues as in Q2 FY14.
o Selling, general and administrative (SG&A) expenses at ₹10.7 billion, 29.7 percent to revenues.